Phio Pharmaceuticals
| Region | Nordamerika |
| ISIN | US71880W2044 |
| Sektor | Biotechnologie |
| Website | http://www.phiopharma.com |
Phio Pharmaceuticals is focused on developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYLTM) therapeutic platform. Immunotherapies harness our immune system to restore surveillance of tumors that evade detection – a potential curative medicine. INTASYLTM therapeutics can be used as a standalone treatment or in combination with other modalities.
| Titel | Autor | Datum |
|---|---|---|
|
In Wahrheit 100 Mal so viel wert?
|
sharedeals | translation missing: de.datetime.time_ago_in_words.almost_x_years |
| Titel | Datum |
|---|---|
| MISC, Samsung Heavy Industries get class approval for world's first ammonia-fuelled LR2 tanker design | vor 20 Tagen |
| Stock Today: MISC Dips Amid Mixed Half-Year Results | vor ungefähr 2 Monaten |
| MISC's First Half Earnings Were Within Expectation | vor ungefähr 2 Monaten |
| MISC earnings outlook in 2H weighed by lower shipping rates, LNG supply delays, say analysts | vor ungefähr 2 Monaten |
| AEON, Ajinomoto, Allianz, Avillion, Bank Islam, Elridge Energy, FGV, Gamuda, GDB, Haily, Hextar, HLIND, Ivory Properties, Kerjaya, Magma,... | vor ungefähr 2 Monaten |
| Diese Aktien könnten Dich auch interessieren | |
|---|---|
| PayPal (1 Artikel) | |
| Palatin Technologies (4 Artikel) | |
| Premier Gold Mines (1 Artikel) | |
| QIAGEN (1 Artikel) | |
| Alle anzeigen | |